Surrogate end points: Studying their benefits, taxonomy, and semantics

BMJ (Online)

Volumn 344, Issue 7842, 2012, Pages

  Aronson, Jeffrey K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DISEASE MARKER; HUMAN; HYPERTENSION; LETTER; PRIORITY JOURNAL; RISK REDUCTION; SEMANTICS; TAXONOMY;

BIOLOGICAL MARKERS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84858997852     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e750     Document Type: Letter

References (4)

1. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. BMJ 2011;343:d7995. (28 December.)
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
3. Aronson JK. Biomarkers and surrogate endpoints in monitoring therapeutic interventions. In: Glasziou P, Irwig L, Aronson JK, eds. Evidence-based medical monitoring: from principles to practice. Wiley-Blackwell, 2008:48-62.
4. Feinstein AR. Clinical biostatistics. XLI. Hard science, soft data, and the challenges of choosing clinical variables in research. Clin Pharmacol Ther 1977;22:485-98. (Pubitemid 8193473)